Metronidazol Braun (Metronidazole)

Metronidazole enters susceptible anaerobic cells and is reduced by microbial enzymes, forming nitro radicals that bind to DNA. This causes strand breakage and blocks nucleic acid synthesis, leading to cell death. The drug’s activation only occurs in low‑oxygen environments, which explains its selective activity against anaerobes and certain protozoa.

The dose of Metronidazol Braun is set by the prescribing clinician based on the type and severity of the infection, patient weight, renal and hepatic function, and any relevant comorbidities. Standard dosing regimens exist for common indications, but individual adjustments may be required, especially in patients with organ impairment.

Metronidazol Braun is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no adequate human studies. It may be used when the potential benefit justifies the potential risk to the fetus. Metronidazole is excreted in breast milk in small amounts; breastfeeding decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Metronidazol Braun. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Metronidazol Braun shares the same class mechanism as other nitroimidazoles such as tinidazole and ornidazole. Compared with tinidazole, metronidazole generally has a shorter half‑life and may require more frequent dosing, but both are effective against anaerobic bacteria and protozoa. Choice of agent often depends on local resistance patterns, patient tolerance, and specific regulatory approvals.

Metronidazol Braun should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Maintaining the cold‑chain ensures drug stability and potency throughout distribution.

Metronidazol Braun is given by intravenous injection under the supervision of a qualified healthcare professional. The infusion rate and duration are determined by the prescribing clinician, taking into account the infection being treated and the patient’s clinical status. Intravenous administration allows rapid achievement of therapeutic plasma concentrations.

Serious adverse events, although rare, include seizures, peripheral neuropathy that may be irreversible, severe skin reactions such as Stevens‑Johnson syndrome, and hepatotoxicity manifested by elevated liver enzymes or jaundice. Prompt recognition and discontinuation of the drug are essential if any of these reactions occur.

Metronidazol Braun is contraindicated in patients with a known hypersensitivity to metronidazole or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, those with a history of neurologic disorders related to metronidazole, and patients who are unable to abstain from alcohol during therapy.